|
本帖最后由 金鹏 于 2015-11-28 09:22 编辑
大意:
我们发现FahCore21兼容性不太好,尤其是Maxwell二代。所以我们把FahCore21的任务类型改为Advanced了,以免普通用户收到他们。
详见V版的新闻贴 http://www.equn.com/forum/forum.php?mod=redirect&goto=findpost&ptid=25057&pid=549044
鉴于导致FahCore21内核包出错因素不仅仅是频率,尤其是Maxwell二代出错概率较高,不建议980TI/980/970/960/950之类卡跑;
对于Kepler的卡特别是780TI/780显卡跑FahCore21内核包有着惊人的提升,PPD直逼GTX970,建议试试
A卡不受影响,自主选择是否跑FahCore21内核包
以上都需注意做好显卡散热/降频/降压等保护功课
November 20, 2015 by Vijay Pande ·
We’ve discovered that the new FahCore_21 is producing more errors than we consider acceptable for some clients. The error rate seems to depend on several factors but most noticeable is that it doesn’t work well with second generation Maxwell GPUs. A few projects have made their way through Advanced testing have been distributed to everyone under the default “FAH” client-type setting. To allow donors to limit this exposure, those projects have been reclassified as “Advanced” which is appropriate for a FahCore that is still under development. As has always been the case, the “Advanced” setting will give you access to newer projects which may have a higher error rate. It is our intention to provide only the safest assignments with the default setting or you can choose to configure your system to run these advanced projects depending on how frequently you encounter these errors. These conditions are expected to improve as new projects, new versions of that FahCore, or new versions of the drivers incorporate whatever fixes are required. In the meantime, Work Units which are completed successfully allow scientific research to progress toward even more challenging projects than we’ve done so far.
Filed Under: Uncategorized ·
mTOR: Projects 10491-10499
November 9, 2015 by Steven Albanese ·
In projects 10491-10499, the Chodera lab takes a look at mTOR, a serine/threonine kinase. The MTOR gene was originally discovered in yeast in 1991 and named TOR1/2 because it was the target of rapamycin, an anti-fungal small molecule isolated from the soil of Easter Island in the 1970s. In 1994, the mammalian target of rapamycin (mTOR) was discovered by Drs. Sabatini, Snyder, Abraham, and Schreiber. mTOR integrates multiple signal inputs to control processes such as cell growth and metabolism, among others. Due to its role in controlling a number of cellular processes, mTOR has clinical significance in neurodegenerative diseases, diabetes and cancer. In the Chodera lab, we are working with the Hsieh lab at MSKCC to understand mTOR’s role in cancer and the development of new and better therapeutics that target it. Currently, the FDA has approved treatment for metastatic clear cell Renal Cell Carcinoma (ccRCC) that includes mTOR inhibitors such as Everolimus and Temsirolimus. An effort to understand the patient-to-patient variation in response to these drugs by studying how extraordinary responders lead to the characterization of mTOR activating missense mutations in these patients. These mutants cluster in two domains of mTOR: the kinase and FAT domains. These projects will allow us to generate a model of the conformations available to mTOR and ultimately to investigate how these clinically relevant mutations might influence the protein’s structure. Both the mTOR kinase domain and the larger construct including the FAT domain are very large systems, exploiting the latest OpenMM GPU core (0×21) and push the capabilities of latest-generation GPUs to their full extent.
p9712, p9704 demoted to advHi,
Until more core21 issues can be resolved, these projects are being demoted to adv.
Thanks to all the donors who persevered and produced some great data
Note: If you didn't see a high error rate with these projects, consider setting your client to ADV
|
|